XOMA (NASDAQ:XOMA) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research report released on Tuesday morning.

Separately, HC Wainwright lowered their target price on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a report on Monday, February 3rd.

XOMA Price Performance

Shares of NASDAQ XOMA opened at $27.06 on Tuesday. The firm’s 50-day moving average price is $26.75 and its 200-day moving average price is $27.96. XOMA has a 1-year low of $19.61 and a 1-year high of $35.00. The firm has a market capitalization of $318.85 million, a P/E ratio of -7.78 and a beta of 0.90. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

Insider Buying and Selling

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On XOMA

A number of institutional investors have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets grew its position in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares in the last quarter. New York State Common Retirement Fund grew its position in XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 800 shares in the last quarter. Wells Fargo & Company MN grew its position in XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,183 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of XOMA during the 4th quarter valued at approximately $206,000. Finally, Rhumbline Advisers grew its position in shares of XOMA by 18.1% during the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 1,699 shares during the period. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.